Do they go with a Covid-19 question? Or one about aducanumab? Maybe a combination of both.
One of biotech’s sell-side analysts — perhaps Geoff Porges from SVB Leerink, or J.P. Morgan’s Cory Kasimov, or Umer Raffat of Evercore ISI — will ask the first question of Biogen (BIIB) chief executive Michel Vounatsos when its first-quarter earnings call kicks off on Wednesday morning.
I hope someone would ask a question about the Chinese biostatistician Dr. Li Zhu who was publicized to have left the company after testing positive for coronavirus, and more importantly whether she had any role in the statistical analysis of aducsnumab (efficacy and/or safety)!
Comments are closed.